Shigella

Intranasal Vaccine Demonstrates Safety, Immunogenicity

Published in Vaccine Weekly, September 5th, 2001

by N.R. Saltmarsh, staff medical writer - A new Shigella flexneri 2a vaccine delivered intranasally could offer as much protection as live vaccines already studied in humans and warrants further consideration, say researchers working in the United States.

L.F. Fries and colleagues tested the vaccine, comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins, in a dose-escalating series of two immunizations. Doses were 0.1, 0.4, 1.0, and 1.5 mg based on protein.

The vaccine elicited S. flexneri* 2a LPS-specific immunoglobulin A (IgA), IgG, and IgM antibody-secreting cells (ASCs)...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2001-09-05)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry